Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: A population-based perspective

Archives of Internal Medicine

Volumn 161, Issue 12, 2001, Pages 1521-1528

  Yarzebski, J ^a   Spencer, F ^a   Goldberg, R J ^a   Lessard, D ^a   Gore, J M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; FEMALE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0034925096     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.12.1521     Document Type: Article

References (42)

1. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
2. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
3. Regression of coronary atherosclerosis: An achievable goal? Review of results from recent clinical trials
4. Preventing heart attack and death in patients with coronary disease
5. The value of lowering cholesterol after myocardial infarction
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
9. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study
10. Detection, evaluation, and treatment of high blood cholesterol in adults: The expert panel
11. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
12. Use of lipid-lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study)
13. Cholesterol awareness after case-finding: Do patients really know their cholesterol numbers?
14. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention?
15. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease
16. How soon after myocardial infarction should plasma lipid values be assessed?
17. Why measure cholesterol after myocardial infarction, and when?
18. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
19. A community-wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease
20. A two-decades (1975-1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: A community-wide perspective
21. Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981): The Worcester Heart Attack Study
22. Cholesterol management in theory and practice
23. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
24. The lipid research clinics coronary primary prevention trial results, II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
25. Cholesterol reduction yields clinical benefit: A new look at old data
26. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
27. Recent trends in the identification and treatment of high blood cholesterol by physicians: Progress and missed opportunities
28. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
29. Smoking cessation after acute myocardial infarction: Effects of a nurse-managed intervention
30. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure
31. Getting cardiologists interested in lipids
32. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction
33. Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis
34. A case-management system for coronary risk factor modification after acute myocardial infarction
35. Hypercholesterolaemia in the elderly: Is drug treatment justified?
36. Cholesterol in the elderly: Is it important?
37. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
38. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrents Events trial
39. The evolving role of statins in the management of atherosclerosis
40. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
41. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient